{"id":"beclometasone","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute tuberculosis","Adrenal cortical hypofunction","Bacterial infectious disease","Bilateral cataracts","Disease caused by parasite","Disease of liver","Epistaxis","Exposure to varicella","Glaucoma","Inactive tuberculosis","Measles","Mycobacteriosis","Mycosis","Nasal Candidiasis","Nasal Septal Ulcers","Nasal Trauma","Ocular hypertension","Operation on nose","Ophthalmic herpes simplex","Perforation of nasal septum","Uncontrolled Bacterial Infections","Untreated Fungal Infection","Varicella-zoster virus infection"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Clenil","Clenil 200"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor"},"_scrapedAt":"2026-03-27T23:39:55.929Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma","diseaseId":"asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma management","diseaseId":"asthma-management","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal polyp","diseaseId":"nasal-polyp","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rhinitis","diseaseId":"rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vasomotor rhinitis","diseaseId":"vasomotor-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04886999","phase":"PHASE3","title":"Study in Adult Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-24","conditions":"Asthma","enrollment":78},{"nctId":"NCT07489911","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","status":"RECRUITING","sponsor":"Chiesi Slovenija, d.o.o.","startDate":"2024-11-04","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":200},{"nctId":"NCT06786767","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting","status":"COMPLETED","sponsor":"Chiesi Bulgaria","startDate":"2025-02-01","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":281},{"nctId":"NCT05970731","phase":"PHASE2","title":"Directed Topical Drug Delivery for Treatment for PASC Hyposmia","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-09-05","conditions":"Post Acute Sequelae Covid-19 Hyposmia","enrollment":16},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":"COPD","enrollment":661},{"nctId":"NCT05168995","phase":"","title":"Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2022-04-12","conditions":"Asthma","enrollment":620},{"nctId":"NCT05888350","phase":"NA","title":"Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-04-01","conditions":"Cough","enrollment":502},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT06871904","phase":"PHASE1, PHASE2","title":"Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2025-04-07","conditions":"Oral Submucous Fibrosis","enrollment":45},{"nctId":"NCT04320342","phase":"PHASE3","title":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-04-28","conditions":"COPD, COPD Exacerbation","enrollment":3433},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT07301736","phase":"PHASE2","title":"Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-12-17","conditions":"Asthma","enrollment":780},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT06480890","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2024-07-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":362},{"nctId":"NCT07267273","phase":"NA","title":"Betamethasone Phonophoresis For Vitiligo","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-11-10","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT07232264","phase":"NA","title":"Respiratory and Peripheral Muscle Strength as Predictors of Inhaler Treatment Response in Asthma: A Comparison of DPI and MDI Devices","status":"COMPLETED","sponsor":"Bugra Kerget","startDate":"2025-03-01","conditions":"Asthma (Diagnosis)","enrollment":80},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT02114034","phase":"","title":"Cohort Analysis of Clinical and Biological Severe Childhood Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-11-12","conditions":"Severe Asthma","enrollment":362},{"nctId":"NCT04902573","phase":"","title":"A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes","status":"COMPLETED","sponsor":"Chiesi UK","startDate":"2021-06-17","conditions":"Asthma","enrollment":147},{"nctId":"NCT06970080","phase":"PHASE4","title":"Therapeutic Relevance of Abnormal Airway Morphology in Asthma","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-02","conditions":"Asthma","enrollment":242},{"nctId":"NCT05292586","phase":"PHASE3","title":"A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-08-31","conditions":"Asthma","enrollment":1377},{"nctId":"NCT05495698","phase":"NA","title":"Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Franciscus Gasthuis","startDate":"2022-12-13","conditions":"Copd, Adherence, Medication","enrollment":300},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT06100042","phase":"","title":"Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiesi Italia","startDate":"2024-04-24","conditions":"Asthma","enrollment":200},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT04937543","phase":"PHASE2","title":"Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2021-06-28","conditions":"Covid19","enrollment":50},{"nctId":"NCT03141424","phase":"PHASE4","title":"Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2022-06-01","conditions":"Asthma","enrollment":20},{"nctId":"NCT06869382","phase":"PHASE4","title":"ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-01-01","conditions":"Asthma Patients","enrollment":26},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1252},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06678191","phase":"","title":"Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting","status":"RECRUITING","sponsor":"Chiesi Hungary Ltd.","startDate":"2024-10-24","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale","enrollment":800},{"nctId":"NCT05018598","phase":"PHASE4","title":"Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-25","conditions":"Asthma","enrollment":320},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69},{"nctId":"NCT00476268","phase":"PHASE3","title":"Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-02","conditions":"Asthma","enrollment":824},{"nctId":"NCT06657066","phase":"PHASE2, PHASE3","title":"EFFECTIVENESS of PROBIOTICS in ADULTS with MODERATE to SEVERE PERSISTENT ASTHMA","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2021-12-06","conditions":"Asthma Patients","enrollment":74},{"nctId":"NCT05830071","phase":"PHASE1","title":"A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-03-29","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":95},{"nctId":"NCT06571942","phase":"PHASE4","title":"Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","status":"RECRUITING","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2023-11-15","conditions":"COPD Bronchitis, Pollution Related Respiratory Disorder","enrollment":128},{"nctId":"NCT06567977","phase":"","title":"TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","status":"RECRUITING","sponsor":"Chiesi Poland Sp. z o.o.","startDate":"2024-08","conditions":"Asthma","enrollment":60},{"nctId":"NCT00395408","phase":"PHASE4","title":"Linear Growth Study (0476-097)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-06","conditions":"Asthma","enrollment":360},{"nctId":"NCT06482294","phase":"PHASE2","title":"CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Università degli Studi di Ferrara","startDate":"2024-06-18","conditions":"Asthma","enrollment":80},{"nctId":"NCT03364959","phase":"NA","title":"Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2018-10-23","conditions":"Asthma in Children","enrollment":60},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT05948891","phase":"","title":"Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study","status":"RECRUITING","sponsor":"Chiesi SAS","startDate":"2023-08-01","conditions":"COPD","enrollment":500},{"nctId":"NCT03341403","phase":"PHASE2, PHASE3","title":"Effect of a Synbiotic \"Probiotical®/Bactecal® \" in Asthma","status":"COMPLETED","sponsor":"University of Liege","startDate":"2017-01-17","conditions":"Asthma","enrollment":55},{"nctId":"NCT04817800","phase":"PHASE1, PHASE2","title":"To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2021-03-25","conditions":"Seasonal Allergic Rhinitis","enrollment":48},{"nctId":"NCT03453112","phase":"PHASE3","title":"Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-10-09","conditions":"Asthma","enrollment":494},{"nctId":"NCT06139029","phase":"EARLY_PHASE1","title":"Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis","status":"COMPLETED","sponsor":"Mardan Medical Complex","startDate":"2022-11-15","conditions":"Acute Bronchiolitis","enrollment":60},{"nctId":"NCT05728749","phase":"","title":"A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes","status":"UNKNOWN","sponsor":"Chiesi SAS","startDate":"2023-03-03","conditions":"ASTHMA","enrollment":300},{"nctId":"NCT05097014","phase":"PHASE4","title":"CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":106},{"nctId":"NCT02517099","phase":"PHASE2","title":"Preschool Wheeze: Inflammation/Infection Guided Management","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-06-05","conditions":"Asthma","enrollment":60},{"nctId":"NCT05748977","phase":"EARLY_PHASE1","title":"Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-20","conditions":"Copd","enrollment":80},{"nctId":"NCT03846570","phase":"PHASE3","title":"Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2019-01-29","conditions":"Bronchiectasis","enrollment":34},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT02995733","phase":"PHASE4","title":"Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-11-27","conditions":"Asthma","enrollment":1220},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT05107440","phase":"NA","title":"BREATHE: Virtual Self-management for Long COVID-19","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2022-01-03","conditions":"COVID-19","enrollment":27},{"nctId":"NCT01244256","phase":"PHASE2, PHASE3","title":"Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated","status":"SUSPENDED","sponsor":"Azidus Brasil","startDate":"2007-04","conditions":"Folliculitis","enrollment":80},{"nctId":"NCT03795350","phase":"PHASE1","title":"Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2019-01-14","conditions":"Chronic Obstructive Pulmonary Disease, Asthma","enrollment":19},{"nctId":"NCT04873063","phase":"PHASE1","title":"Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"SOFAR S.p.A.","startDate":"2021-10-22","conditions":"Healthy Adult Male Volunteers","enrollment":28},{"nctId":"NCT05352191","phase":"PHASE4","title":"Beclomethasone in Healthy Athletes","status":"UNKNOWN","sponsor":"Western Norway University of Applied Sciences","startDate":"2022-09-01","conditions":"Performance, Detection, Doping","enrollment":30},{"nctId":"NCT02351180","phase":"PHASE1, PHASE2","title":"Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-01","conditions":"Lung Transplant Infection","enrollment":16},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT03855189","phase":"PHASE3","title":"Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1993-08-23","conditions":"Seasonal Allergic Rhinitis","enrollment":345},{"nctId":"NCT03879772","phase":"PHASE3","title":"Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1996-03-12","conditions":"Rhinitis, Allergic, Seasonal","enrollment":679},{"nctId":"NCT00911547","phase":"PHASE3","title":"The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-03","conditions":"Asthma","enrollment":642},{"nctId":"NCT04671355","phase":"PHASE4","title":"TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD","status":"WITHDRAWN","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-04","conditions":"COPD","enrollment":""},{"nctId":"NCT04876677","phase":"PHASE3","title":"Functional Respiratory Imaging Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT03084718","phase":"PHASE2","title":"An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"Asthma","enrollment":610},{"nctId":"NCT00109668","phase":"PHASE3","title":"Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-07-31","conditions":"Asthma","enrollment":415},{"nctId":"NCT03036267","phase":"NA","title":"Feasibility of the BREATHE Asthma Intervention Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-04-04","conditions":"Asthma Chronic, Health Behavior","enrollment":46},{"nctId":"NCT01024608","phase":"PHASE3","title":"Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-12-31","conditions":"Seasonal Allergic Rhinitis, Hay Fever","enrollment":340},{"nctId":"NCT00988247","phase":"PHASE3","title":"Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-10-31","conditions":"Rhinitis, Allergic, Perennial","enrollment":529},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT03627858","phase":"","title":"Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting","status":"COMPLETED","sponsor":"Chiesi SA/NV","startDate":"2018-08-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":149},{"nctId":"NCT00071552","phase":"PHASE4","title":"Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-01-31","conditions":"Asthma","enrollment":49},{"nctId":"NCT00094016","phase":"PHASE3","title":"Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-10-31","conditions":"Asthma","enrollment":440},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT05114434","phase":"","title":"Effect of BDP/Formoterol/G on Cough Efficacy in Moderate to Severe COPD Patients (EFFICACE)","status":"UNKNOWN","sponsor":"University of Parma","startDate":"2021-11","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":40},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT02030457","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Pharmacokinetics","enrollment":72},{"nctId":"NCT02000609","phase":"PHASE2","title":"A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of \"Nexthaler\" Dry Powder Inhaler in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2013-12","conditions":"COPD","enrollment":49},{"nctId":"NCT02119234","phase":"PHASE1","title":"Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":"COPD","enrollment":36},{"nctId":"NCT00929851","phase":"PHASE3","title":"BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1199},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT01917331","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1368},{"nctId":"NCT01343745","phase":"PHASE2","title":"Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-02","conditions":"Mild Persistent Asthma","enrollment":18},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3686},{"nctId":"NCT01176747","phase":"PHASE1, PHASE2","title":"Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma","enrollment":28},{"nctId":"NCT02040597","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":42},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":"Asthmatic","enrollment":30},{"nctId":"NCT01476813","phase":"PHASE2","title":"Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":281},{"nctId":"NCT00476099","phase":"PHASE3","title":"Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":828},{"nctId":"NCT00000752","phase":"PHASE2","title":"Preventing Frequent Sinus Infections in HIV-Infected Patients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Sinusitis","enrollment":""}],"whoEssential":true,"_emaApprovals":[],"_faersSignals":[{"count":294,"reaction":"DYSPNOEA"},{"count":194,"reaction":"MALAISE"},{"count":193,"reaction":"NAUSEA"},{"count":185,"reaction":"DIZZINESS"},{"count":177,"reaction":"HEADACHE"},{"count":146,"reaction":"FATIGUE"},{"count":142,"reaction":"DIARRHOEA"},{"count":132,"reaction":"VOMITING"},{"count":131,"reaction":"PYREXIA"},{"count":126,"reaction":"PNEUMONIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":269,"therapeuticAreas":["Respiratory"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Beclometasone","genericName":"Beclometasone","companyName":"Imperial College London","companyId":"imperial-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}